{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:46:17Z","timestamp":1785228377278,"version":"3.55.0"},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.acuro.2017.03.003","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T06:30:13Z","timestamp":1493361013000},"page":"590-595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Tratamiento adyuvante intravesical en c\u00e1ncer de vejiga no m\u00fasculo invasivo: importancia de la cepa y el mantenimiento"],"prefix":"10.1016","volume":"41","author":[{"given":"F.","family":"Guerrero-Ramos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Lara-Isla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Justo-Quintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Duarte-Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"de la Rosa-Kehrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Villacampa-Aub\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acuro.2017.03.003_bib0080","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: Acombined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model","volume":"182","author":"Fernandez-Gomez","year":"2009","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0090","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0095","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0022-5347(05)64043-8","article-title":"Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity","volume":"169","author":"B\u00f6hle","year":"2003","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.urology.2003.11.049","article-title":"Intravesical bacille Calmette-Gu\u00e9rin versus mitomycin C in superficial bladder cancer: Formal meta-analysis of comparative studies on tumor progression","volume":"63","author":"B\u00f6hle","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.acuro.2017.03.003_bib0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group Study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.eururo.2014.02.061","article-title":"Bacillus Calmette-Gu\u00e9rin strain differences have an impact on clinical outcome in bladder cancer immunotherapy","volume":"66","author":"Rentsch","year":"2014","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0115","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.juro.2013.01.084","article-title":"A prospective comparative study of intravesical bacillus Calmette-Gu\u00e9rin therapy with the Tokyo or Connaught strain for nonmuscle invasive bladder cancer","volume":"190","author":"Sengiku","year":"2013","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2016.05.033","article-title":"The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer","volume":"34","author":"Witjes","year":"2016","journal-title":"Urol Oncol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0125","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstr\u00f6m","year":"2009","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0135","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.acuro.2015.12.009","article-title":"Estudio retrospectivo de diferentes opciones de tratamiento conservador con bacilo de Calmette-Gu\u00e8rin en el carcinoma urotelial vesical T1G3: terapia de mantenimiento","volume":"40","author":"Palou-Redorta","year":"2016","journal-title":"Actas Urol Esp."},{"key":"10.1016\/j.acuro.2017.03.003_bib0140","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: One-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0145","first-page":"8","article-title":"Molecular, preclinical, and clinical comparative data regarding different strains of bacillus Calmette-Gu\u00e9rin (BCG): Review by the French Urological Association Oncology Committee (CCAFU)","volume":"26","author":"Neuzillet","year":"2016","journal-title":"Prog En Urol."},{"key":"10.1016\/j.acuro.2017.03.003_bib0150","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: Results from a European organisation for research and treatment of cancer genito-urinary group phase iii trial","volume":"44","author":"Van der Meijden","year":"2003","journal-title":"Eur Urol."}],"container-title":["Actas Urol\u00f3gicas Espa\u00f1olas"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480617300621?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210480617300621?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T08:56:56Z","timestamp":1535878616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210480617300621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0210480617300621"],"URL":"https:\/\/doi.org\/10.1016\/j.acuro.2017.03.003","relation":{},"ISSN":["0210-4806"],"issn-type":[{"value":"0210-4806","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tratamiento adyuvante intravesical en c\u00e1ncer de vejiga no m\u00fasculo invasivo: importancia de la cepa y el mantenimiento","name":"articletitle","label":"Article Title"},{"value":"Actas Urol\u00f3gicas Espa\u00f1olas","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acuro.2017.03.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 AEU. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}